Multiple Myeloma · line 1 · Bortezomib + Lenalidomide + Dexamethasone (VRd), 4-6 induction cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-VRD`

ID	`IND-MM-ELDERLY-FRAIL-VRD-LIGHT`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-MM`
Sources	`SRC-EHA-EMN-MM-2025` `SRC-ESMO-MM-2023` `SRC-NCCN-MM-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Special-population indication for elderly (≥75) and/or frail MM 1L. Missing entity flag: dedicated REG-VRD-LITE + REG-D-RD-MAIA — author in PROD-2.

Used By

Handbook Chapters

HB-MM-1L - Multiple myeloma: first-line risk and fitness reasoning